PFS
Figure 1 · Panel A
Panel A 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
R Fazio, G Randon, F Bergamo, F Palermo, S Tamberi, E Giommoni, S Di Donato, L Fornaro, O Brunetti, F De Vita, M Valgiusti, S M Gobba, A Spallanzani, S Murgioni, V Bethaz, A Strippoli, T P Latiano, G G Cardellino, C Ceccon, A Raimondi, M Prisciandaro, C C Pircher, M Ambrosini, P Manca, M Fassan, M Di Bartolomeo, M Di Maio, F Pietrantonio
ESMO Open 10(7) 105329
BACKGROUND: There is a growing interest in optimizing the therapeutic management of older cancer patients as well as understanding the sex-specific differences in terms of efficacy and safety of cancer treatments. However, limited data are available on the initial therapy of patients with advanced gastro-oesophageal cancer. MATERIALS AND METHODS: The ARMANI phase III trial showed progression-free survival (PFS) and overall survival (OS) benefit with paclitaxel plus ramucirumab switch maintenance (arm A) versus the continuation of first-line oxaliplatin and fluoropyrimidine (arm B) in patients with advanced human epidermal growth factor receptor 2-negative gastric or gastro-oesophageal junction cancer. We conducted a subgroup analysis aimed at assessing the differences in efficacy, safety and quality of life (QoL) according to age (<70 versus ≥70 years) and sex. RESULTS: No significant differences in terms of PFS (P = 0.757), OS (P = 0.588) and overall response rates (ORRs) (P = 0.238) were observed between older and younger patients. No significant differences in PFS (P = 0.646), OS (P = 0.858) and ORRs (P = 0.649) were observed between females and males. The effect of treatment arm on survival outcomes was similar across age (P = 0.094) and sex groups (P = 0.469). Looking at specific adverse events, peripheral neuropathy occurred more frequently in younger patients (P = 0.020), anaemia in older patients (P = 0.044) and hand-foot syndrome in women (P = 0.021). Older patients were less likely to receive a post-discontinuation treatment (P = 0.010), especially in arm B (P = 0.026). The impact on QoL was better in arm A, irrespective of age and sex. CONCLUSION: The ARMANI trial supported the benefit of the investigated switch maintenance strategy irrespective of age and sex.
2 个 Figure · 8 个 KM 面板
Figure 1 Survival analysis according to age . Kaplan–Meier curves for progression-free survival (PFS) and overall survival (OS) in patients stratified according to (A, B) age (<70 and ≥70 years) and (C, D) age and treatment arm (<70 years arm A, <70 years arm B, ≥70 years arm A and ≥70 years arm B). CI, confidence interval; HR, hazard ratio.
Figure 1 · Panel A
Panel A 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 1 · Panel B
Panel B 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 1 · Panel C
Panel C 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 1 · Panel D
Panel D 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 Survival analysis according to sex . Kaplan–Meier curves for progression-free survival (PFS) and overall survival (OS) in patients stratified according to (A, B) sex (female and male) and (C, D) sex and treatment arm (female arm A, female arm B, male arm A and male arm B). CI, confidence interval; HR, hazard ratio.
Figure 2 · Panel A
Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel B
Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel C
Panel C 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel D
Panel D 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。